预后变量:年龄、IPSS-R分数、EZH2、SF3B1、TP53 计算公式:年龄×0.04+IPSS-R分数×0.3+EZH2×0.7+SF3B1×0.5+TP53×1 11、MDS细胞遗传学分类[11] 12、骨髓增生异常综合征共病评估(ACE-27)[12] 参考文献(向下滑动) [1] Greenberg P, Cox C, LeBea...
②常规利用FISH检测手段寻找细胞遗传学证据,可减少MDS的漏诊率。③较长的病程及不良的骨髓细胞核型是影响RCC患儿病情程度的重要因素。④IPSS-R积分系统的使用,可以避免部分RCC患儿的病情被低估。 关键字:儿童 骨髓增生异常综合征 细胞遗传学 IPSS-R The Application of Revised International Prognostic Score System in...
The aims of the present study were to describe characteristics of patients included in this intermediate group of the IPSS-R in the Spanish MDS cohort and to identify which factors could have an impact on survival. A new score prognostic system (GESMDi score) in order to a better ...
均有统计学意义(Tarone-Ware为9.572~19.834,P0.05).WPSS生存曲线各组相交多,IPSS-R生存曲线各组交叉少,IPSS,WPSS对低危组预后评估不佳,IPSS-R最佳.IPSS与IPSS-R相关性最强(rs=0.765,P0.05).结论:IPSS,WPSS,IPSS-R对初治MDS患者的预后评估均有意义,IPSS-R最具优势,临床工作中3种方法联合更有利于MDS预后...
Study supported by the MDS Foundation. IPSS-M Very Low Low Moderate Low Moderate High High Very High Patients, % (n=2,701) 14% (381) 33% (889) 11% (302) 11% (281) 14% (379) 17% (469) Risk score ≤–1.5 >–1.5 to –0.5 >–0.5 to 0 > 0 to 0.5 > 0.5 to ...
More collaboration, education needed to untangle complexity of MDS diagnosis Three patients included in this study were divided into three groups as mild, moderate, and severe on the basis of the International Prostate Symptom Score (IPSS) (Tables 2-5). Evaluation of benign prostatic hyperplasia: ...
We first focused on MDS patients classified according to World Health Organization criteria. The IPSS-R score significantly affected OS (HR, 1.41; P < .001) and probability of relapse (HR, 1.81; P < .001). The prognostic effect of IPSS-R on posttransplant outcome was also maintained when...
IPSS-R score could be applied in AML population and keep his prognostic impact in AML patients treated by AZA. IPSS-R score should be evaluated in larger cohort of MDS and AML patients treated by AZA in order to confirm these results. Disclosures No relevant conflicts of interest to declare...
Background: Myelodysplastic syndrome (MDS) therapeutic decisions have been traditionally based on the IPSS; however, this score system does not allow the identification of patients with low risk disease (low or intermediate-1 IPSS) but a... H Pomares,I. Sánchez-Ortega,E Alonso,... - 《Bloo...
Furthermore, patients with a poor-risk karyotype appear to do significantly worse with RICT 45, 46. Although an impressive 3-year disease-free survival (DFS) of 41% has been reported using FBC conditioning prior to unrelated donor blood SCT in MDS [47], 90% of the patients in this ...